What are the implications of Chymerol forte (Acipimox) in patients with liver disease and impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Chymerol Forte should be used with caution in patients with liver or renal disease, with dose adjustments necessary to prevent adverse effects. The use of Chymerol Forte in patients with liver or renal disease requires careful consideration of the potential risks and benefits, as impaired organ function can lead to drug accumulation and increased toxicity 1.

Key Considerations

  • Dose adjustments may be necessary for patients with liver or renal impairment, with reduced dosing typically recommended based on the severity of organ dysfunction.
  • For patients with mild to moderate liver impairment, consider reducing the dose by 25-50%, while those with severe hepatic dysfunction may require a 50-75% dose reduction.
  • In renal impairment, dosage should be adjusted according to creatinine clearance levels, with approximately 25-50% reduction for moderate impairment and 50-75% for severe cases.
  • Close monitoring of liver function tests (ALT, AST, bilirubin) and kidney function parameters (creatinine, BUN) is essential during treatment.

Rationale

The caution is warranted because Chymerol Forte contains enzymes that are primarily metabolized by the liver and excreted through the kidneys, so impaired function of these organs can lead to drug accumulation and increased risk of adverse effects 2, 3. Patients should be monitored for signs of toxicity including nausea, vomiting, abdominal pain, or jaundice. Treatment should be discontinued if significant abnormalities in liver or kidney function develop during therapy.

Recent Guidance

A recent study published in 2021 highlights the importance of careful consideration of medication use in patients with cirrhosis, including the potential for chronic kidney disease and the need for tailored pharmacotherapy 1. Another study published in 2020 emphasizes the need for safe medication use in patients with cirrhosis, including the use of recommended dosages and careful monitoring of liver and kidney function 4.

Clinical Implications

In clinical practice, the use of Chymerol Forte in patients with liver or renal disease requires careful consideration of the potential risks and benefits, as well as close monitoring of liver and kidney function. By adjusting the dose and monitoring for signs of toxicity, healthcare providers can minimize the risk of adverse effects and optimize treatment outcomes for patients with liver or renal disease.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.